US Stock Movement: Eli Lilly surged on October 20 as Omvoh's pediatric indication and Phase III trial reached endpoints
Bitget异动解读2026/10/20 13:41Eli Lilly's Surge on October 20 Interpreted
Keywords: Omvoh pediatric indication, phase III trial reached endpoint
On October 19, Eli Lilly announced that the phase III SHINE-2 study of Omvoh for the treatment of pediatric ulcerative colitis had reached its primary endpoint; among 52 patients aged 6 to 17 who responded to Omvoh, 50% achieved clinical remission at week 52. The company plans to submit the study results to global regulatory agencies to seek an expansion of the drug’s indication.
(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The pound rises to a four-week high, with attention on UK CPI and budget risks.
Crypto prices
More
